Memorial Sloan Kettering Validation of LAG-3 impact

From memorial Sloan Kettering in NY

The immunotype that jumped out was a group of patients who had high levels of a protein called LAG-3 expressed on various T cell subsets. Patients with this LAG+ immunotype, the team found, had a much shorter survival time compared with patients with a LAG- immunotype: For melanoma patients, there was a difference in median survival of more than four years (22.2 months compared with 75.8 months) and the difference was statisticallysignificant

To me the more confirmation the more confident I become. The part that jumps out to me, is where she talks about not looking particularly at lag-3 but following the data led them to this discovery.


https://www.sciencedaily.com/releases/2021/08/210825153747.htm